BDSI says drug does well in phase I study - Triangle Business Journal:

otomaqaqaba.blogspot.com
The Raleigh-based company (Nasdaq: reported the results of the phase I trial of BioraolAmphotericin B, an antifungal drug. Phas I trials are early-stage studies that give preliminary measured of the safety of a how well patients toleratea drug, and how the drug reacta in the body. Later, larger clinical trials measurre how well adrug works; they also provide a widefr array of safety BDSI says its tests show that Bioral Amphotericin B was safe and Preliminary evaluations also showed promise in the pharmacokineticzs of the drug, a measure of how the body reacted to the “This study provides the important initial support for us to progressa the clinical development of Bioral Amphotericihn B,” David Blum, BDSI’s vice president of clinical researcu and medical affairs, said in a writtehn statement.
The drug Amphotericin B is widely used to trea tfungal infections, but it can be administered only BDSI’s drug uses the company’s Bioral technology in an effort to create an oral form of the Bioral Amphotericin B is the lead compound in BDSI’sd Bioral pipeline. The company’s overall lead product, a painkilletr used in cancer patients known as awaits Food and Drug Administration approval some time this springor